Medullary Thyroid Cancer (MTC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Medullary Thyroid Cancer (MTC) Market Outlook

Thelansis’s “Medullary Thyroid Cancer (MTC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Medullary Thyroid Cancer (MTC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Medullary Thyroid Cancer (MTC) Overview

Medullary Thyroid Cancer (MTC) originates from the parafollicular cells, also known as C cells, of the thyroid gland, which produces calcitonin. This tumor is derived from neural crest cells and is characterized by elevated calcitonin levels. About 75-80% of medullary thyroid cancers are sporadic, while the remaining cases are familial and occur in multiple endocrine neoplasias (MEN) 2A, MEN 2B, and familial medullary thyroid cancer (FMTC). The development of MTC can be attributed to RET mutations in the neural crest tissue of the thyroid gland. Germline mutations are associated with MEN2 and FMTC medullary thyroid cancers, while 40-50% of sporadic medullary thyroid cancers have acquired RET mutations. Medullary thyroid cancer associated with multiple MEN syndromes is often multicentric and bilateral, whereas sporadic medullary thyroid cancer is usually unilateral. These tumors typically involve the upper portions of both lobes of the thyroid gland since C cells are predominantly located in the upper poles of the gland. Paraneoplastic syndromes, such as Cushing syndrome and carcinoid syndrome, can also occur in MTC, producing hormones such as corticotropin, serotonin, prostaglandins, and melanin. The five-year survival rate for stages 1 to 3 of medullary thyroid cancer is 93%, whereas, for stage 4, it is only 28%. Surgical resection is the primary treatment for medullary thyroid carcinoma, as this cancer does not respond to conventional chemotherapy or radioactive iodine (RAI).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Medullary Thyroid Cancer (MTC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment